Vesna Šneller

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier et al. · Journal of Clinical Oncology · 2010 · 808 citations

Medicine, Oncology, Pharmacotherapy +12

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Tanja Trarbach, Markus Moehler, Volker Heinemann et al. · British Journal of Cancer · 2010 · 180 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

Martin R. Stockler, Felix Hilpert, Michael Friedländer et al. · Journal of Clinical Oncology · 2014 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

Sergio Bracarda, Joaquim Bellmunt, Bohuslav Melichar et al. · British Journal of Urology · 2010 · 49 citations

Medicine, Oncology, Pharmacotherapy +14

Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin’s lymphoma

J. M. Vose, Vesna Šneller · Annals of Oncology · 2003 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +10